Prior Authorization: Evidence-Dependent

Prior authorization may be required and is evidence-dependent. Determinations for coverage of EECP/ECP will consider the clinical evidence described in this policy (including that findings for newer indications such as Long COVID are hypothesis-generating) and member-specific plan provisions. Refer to the plan's Clinical Policy Bulletin and member benefits for specific prior authorization rules.

• Prior authorization: contact the payer or consult the Clinical Policy Bulletin to confirm whether prior authorization is required for the member’s plan.
• Evidence-dependent: requests for ECP for indications outside the core medically necessary criteria (e.g., Long COVID) will be reviewed in light of available evidence; promising but hypothesis-generating findings are not sufficient by themselves to establish coverage.
• When prior authorization is required, submit documentation showing the member meets medical necessity criteria (see policy Section I.A.) and any prior authorization forms or clinical notes requested by the payer.

Documentation Requirements

Documentation must clearly support that the member has disabling chronic stable angina refractory to maximum medical therapy and is not readily amenable to surgical intervention, or meets the repeat-course criteria. Retain and submit all supporting records with authorization requests and claims.

• Document NYHA angina class (Class III or IV) and description of disabling symptoms.
• Document attempts and failure or intolerance of maximum medical therapy and why revascularization (PTCA or CABG) is not suitable (inoperable anatomy, high operative risk, or significant comorbidities).
• For repeat courses, document prior ECP response (≥25% reduction in angina frequency or improvement by ≥1 angina class) and that ≥3 months have elapsed since prior treatment.

Billing / Claim Denial Risk

Billing/claim denials may occur if ECP is billed using codes outside the covered code set or for experimental/noncovered indications. Use the covered HCPCS/CPT and ICD-10 codes only when selection criteria are met.

• Covered HCPCS: G0166 (External counterpulsation, per treatment session) when selection criteria are met.
• Do not bill for ECP using codes that correspond to indications listed as experimental/investigational in this policy (examples include fatigue/malaise, erectile dysfunction, Long COVID, heart failure, COPD exercise endurance).
• Claims lacking required documentation or billed for noncovered indications may be denied.

Evidence Limitation / Hypothesis-Generating Findings

Findings described in the literature for newer or nontraditional indications (for example, Long COVID) are hypothesis-generating and require broader clinical investigation; absence of guideline endorsement or inclusion in UpToDate/ACC guidance limits their weight for coverage decisions.

• Studies reporting benefit in Long COVID and other novel indications used validated outcome measures (PROMIS Fatigue, Seattle Angina Questionnaire [SAQ], Duke Activity Status Index [DASI], 6-minute walk distance [6MWD], CCS angina grade, Rose Dyspnea Scale, PHQ-9).
• Because these findings are preliminary, coverage for such indications will generally be considered investigational/experimental unless and until stronger evidence and guideline endorsement emerge.

Provider Responsibilities

Provider responsibility: providers are responsible for treatment decisions and must follow the Clinical Policy Bulletin and the member’s plan provisions when requesting authorization or submitting claims.

• Verify member benefits and prior authorization requirements before scheduling ECP.
• Provide complete clinical documentation with authorization requests and claims to reduce administrative delays or denials.
• Clinical Policy Bulletins guide administration but do not guarantee coverage; payers may update policies and plan provisions may vary.